Pulsatile high-dose treatment with antiangiogenic tyrosine kinase inhibitors improves clinical antitumor activity.

ABSTRACT:

SUBMITTER: Rovithi M 

PROVIDER: S-EPMC5511614 | biostudies-literature | 2017 Aug

REPOSITORIES: biostudies-literature